Prelude Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Prelude Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,758	Closed	-$8K	–	2426
2018 Q4	$8K	Buy	+2,758	New	+$7.58K	﹤0.01%	1442
2017 Q4	–	Sell	-67,233	Closed	-$228K	–	1984
2017 Q3	$228K	Buy	67,233 +39,933	+146%	+$111K	0.02%	605
2017 Q2	$67K	Sell	27,300 -79,800	-75%	-$184K	0.01%	906
2017 Q1	$243K	Buy	107,100 +33,900	+46%	+$75K	0.02%	500
2016 Q4	$155K	Buy	73,200 +34,071	+87%	+$95.1K	0.02%	673
2016 Q3	$131K	Buy	39,129 +9,329	+31%	+$29.6K	0.01%	726
2016 Q2	$94K	Buy	+29,800	New	+$99.4K	0.01%	792
2015 Q4	–	Sell	-34,458	Closed	-$173K	–	1936
2015 Q3	$173K	Buy	+34,458	New	+$197K	0.03%	656
2015 Q2	–	Sell	-4,500	Closed	-$32K	–	2378
2015 Q1	$32K	Hold	4,500	–	–	﹤0.01%	1653
2014 Q4	$35K	Buy	+4,500	New	+$35.6K	0.01%	1550
2014 Q3	–	Sell	-13,800	Closed	-$134K	–	2435
2014 Q2	$134K	Buy	13,800 +7,000	+103%	+$62.4K	0.02%	942
2014 Q1	$57K	Sell	6,800 -2,520	-27%	-$21.6K	0.01%	1263
2013 Q4	$79K	Buy	9,320 +5,120	+122%	+$43.1K	0.01%	954
2013 Q3	$33K	Buy	+4,200	New	+$33.8K	0.01%	1088

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Prelude Capital Management's PDLI Position: Q1 2019 in Review

Prelude Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2019, closing a stake of 2,758 shares — an estimated $8K sold.

Prelude Capital Management first reported a position in PDLI in Q3 2013 and held it in 14 quarters. The position peaked at $243K in Q1 2017. 157 funds tracked by Wall St. Rank hold PDLI as of Q1 2019.

Prelude Capital Management reported no remaining PDL BioPharma, Inc. position as of Q1 2019 after selling out during the quarter.
Prelude Capital Management sold 2,758 PDL BioPharma, Inc. shares in Q1 2019, an estimated $8K.
Prelude Capital Management first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 14 quarters.
Prelude Capital Management's PDL BioPharma, Inc. position peaked at $243K in Q1 2017.
157 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2019.

Based on Prelude Capital Management's 13F filing for Q1 2019, filed 15 May 2019.